Bringing health economic modeling to the 21st century

Value in Health

Volumn 9, Issue 3, 2006, Pages 168-178

  Eddy, David ^a  

^a Archimedes Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; HEALTH ECONOMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBABILITY; REGRESSION ANALYSIS; THEORETICAL MODEL;

EID: 33646264560     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2006.00097.x     Document Type: Conference Paper

References (23)

1. Gersh W Eddy DM Dong E Cardiac arrhythmia classification: a heart-beat interval-markov chain approach Comput Biomed Res 1970 4 385 92
2. Frick MH Elo O Haapa K et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease N Engl J Med 1987 317 1237 45
3. The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease JAMA 1984 251 351 64
4. Shepherd J Cobbe SM Ford I et al. Prevention of coronary heart disease with Pravastatin in men with hypercholesterolemia N Engl J Med 1995 333 1301 7
5. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomized placebo-controlled trial Lancet 2002 360 23 33
6. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of Ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy Lancet 2000 355 253 9
7. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 1998 339 1349 57
8. Sacks FM Pfeffer MA Moye LA et al. The effect of Pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 1996 335 1001 9
9. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 1994 344 1383 9
10. Eddy DM A methodology for evaluating breast cancer screening programs Proceedings of the International Conference on Cybernetics and Society November, 1976
11. Eddy DM Guidelines for the cancer-related checkup: recommendations and rationale CA Cancer J Clin 1980 30 193 240
12. Gold MR Siegel JE Russell LB Weinstein MC Cost-Effectiveness in Health and Medicine New York Oxford University Press 1996
13. Brody JE Cancer society reports it finds some detection tests unneeded New York Times March 21, 1980 p. 1
14. Eddy DM The frequency of cervical cancer screening. Comparison of a mathematical model with empirical data Cancer 1987 60 1117 22
15. Eddy DM Screening for Cancer: Theory, Analysis and Design
16. Lanchester Prize, 1980. Available from: [Accessed November 14, 2005].
17. Schlessinger L Eddy DM Archimedes: a new model for simulating health care systems: the mathematical formulation J Biomed Inform 2002 35 37 50
18. Eddy DM Schlessinger L Archimedes. a trial-validated model of diabetes Diabetes Care 2003 26 3093 101
19. Eddy DM Schlessinger L Validation of the Archimedes diabetes model Diabetes Care 2003 26 3102 10
20. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 1998 352 837 52
21. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 1993 329 977 86
22. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 2002 356 393 402
23. Colhoun HM Betteridge DJ Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomized placebo-controlled trial Lancet 2004 364 685 96